Addex Therapeutics Ltd (NASDAQ:ADXN) Shares Sold by Armistice Capital LLC

Armistice Capital LLC lowered its position in Addex Therapeutics Ltd (NASDAQ:ADXNFree Report) by 92.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 43,000 shares of the company’s stock after selling 494,000 shares during the quarter. Armistice Capital LLC’s holdings in Addex Therapeutics were worth $260,000 at the end of the most recent quarter.

Addex Therapeutics Price Performance

Shares of Addex Therapeutics stock traded down $0.11 on Wednesday, hitting $8.81. The company’s stock had a trading volume of 304 shares, compared to its average volume of 16,063. Addex Therapeutics Ltd has a 52-week low of $5.00 and a 52-week high of $27.90. The firm has a fifty day moving average price of $13.46 and a 200-day moving average price of $10.16.

Addex Therapeutics (NASDAQ:ADXNGet Free Report) last announced its earnings results on Thursday, April 18th. The company reported ($4.06) earnings per share (EPS) for the quarter. The business had revenue of $0.21 million for the quarter. Addex Therapeutics had a negative return on equity of 277.56% and a negative net margin of 644.66%. On average, equities research analysts predict that Addex Therapeutics Ltd will post -11.8 EPS for the current fiscal year.

Addex Therapeutics Company Profile

(Free Report)

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.

Read More

Want to see what other hedge funds are holding ADXN? Visit to get the latest 13F filings and insider trades for Addex Therapeutics Ltd (NASDAQ:ADXNFree Report).

Receive News & Ratings for Addex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addex Therapeutics and related companies with's FREE daily email newsletter.